<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18159">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01706510</url>
  </required_header>
  <id_info>
    <org_study_id>ISSBRIL0076</org_study_id>
    <nct_id>NCT01706510</nct_id>
  </id_info>
  <brief_title>Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients</brief_title>
  <official_title>A Single Center, Randomized, Open Label, Multiple Dose, Crossover Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients With Stable Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rapid City Regional Hospital, Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rapid City Regional Hospital, Inc</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the pharmacodynamic effect of ticagrelor vs. Clopidogrel in American Indian patients
      with stable coronary artery disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Single Center, Randomized, Open Label, Multiple Dose, Crossover Study of the Antiplatelet
      Effects of Ticagrelor Versus Clopidogrel in American Indian Patients With Stable Coronary
      Artery Disease
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Compare ticagrelor's versus clopidogrel's inhibition of the P2Y12 receptor as measured by the decrease in P2Y12 Reaction Units (PRU) using VerifyNow TM.</measure>
    <time_frame>At 2 hour time point after loading dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the decrease of P2Y12 Reaction Units (PRU) by VerifyNow TM from ticagrelor and clopidogrel.</measure>
    <time_frame>0.5 and 8 hour time points after loading dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the decrease in P2Y l2 Reaction Units (PRU) by VerifyNow™ from ticagrelor's and clopidogrel's morning dose on Day 7</measure>
    <time_frame>At the 2, 8, and 24 hours after the last dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate and compare the pharmacodynamic effects, measured by the vasodilator-stimulated phosphoprotein (VASP) assay (platelet reactivity index [PRI]), in all subjects</measure>
    <time_frame>Day1: pre-dose, 0.5, 2, and 8 hours post loading dose Day 7: pre-dose, 2 and 8 hours post dose Day 8: 24 hours post final dose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess and to compare the percentage of subjects with High on-treatment Platelet Reactivity (HPR) at all time points after randomized study treatment.</measure>
    <time_frame>Day 1: Pre-dose, 0.5, 2 and 8 hours post loading dose Day 7: pre-dose, 2 and 8 hours post dose Day 8: 24 hours after final dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>The High on-treatment Platelet Reactivity will be defined in accordance with the following platelet inhibition level cut-off.
&gt; 208 PRU by the VerifyNow P2Y12 assay
&gt; 230 PRU by the VerifyNow P2Y12 assay
&gt; 50% PRI by the VASP assay</description>
  </secondary_outcome>
  <other_outcome>
    <measure>CYP2C19 genotyping to identifying the wild-type CYP2C19 allele (*1), and characterize common alleles known to effect the metabolism of clopidogrel (*2, *3, *4,*5,*6,*7,*8 responsible for poor metabolism and *17 allele responsible for rapid metabolism).</measure>
    <time_frame>One time-point</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel 600 mg Loading Dose followed by 75 mg Daily for 7 days ± 2 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Brand Name: Brilinta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 600 mg loading dose followed by 75 mg Daily for 7 days ± 2 days</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Brand Name: Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented stable CAD fulfilling any of the following, and taking 81mg ASA daily
             treatment:

          -  Females must be post menopausal for at least one year or surgically sterile for at
             least 6 months and negative urine pregnancy test

          -  Self-identified as American Indian

          -  Genetic Inclusion Criteria: must sign the informed consent for genetic and biological
             sample banking.

        Exclusion Criteria:

          -  Any indication for oral anticoagulant or dual antiplatelet treatment

          -  Concomitant therapy with strong CYP3A inhibitors, CYP3A substrates with narrow
             therapeutic index, or strong CYP3A inducers within 14 days and during study treatment
             and during:

          -  Increased bleeding risk including:

          -  Diabetic patients with HbAlC &gt; 10% at screening

          -  Contraindication to clopidogrel, ASA, or ticagrelor -  A history of alcohol and/or
             substance abuse that could interfere with conduct of the trial

          -  Patients requiring dialysis

          -  Patients scheduled for revascularization (e.g., PCI, CABG) during the study period

          -  Any acute or chronic unstable condition in the past 30 days

          -  Known active or recurrent hepatic disorder

          -  Patients who had ACS or stent placed within 12 months of screening

          -  History of Uric Acid nephropathy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James S Walder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rapid City Regional Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roger E DeRaad, MN, CNP</last_name>
    <phone>605-381-5621</phone>
    <email>rderaad@regionalhealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Denice Hockett, RN</last_name>
    <phone>605-718-2610</phone>
    <email>dhockett@regionalhealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Regional Heart Doctors/Black Hills Cardiovascular Research</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger E DeRaad, MN, CNP</last_name>
      <phone>605-718-2610</phone>
      <email>rderaad@regionalhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Denice Hockett, RN</last_name>
      <phone>605-718-2610</phone>
      <email>dhockett@regionalhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>James S Walder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roger E DeRaad, MN, CNP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 10, 2013</lastchanged_date>
  <firstreceived_date>October 10, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clopidogrel</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Myocardial Ischemia</keyword>
  <keyword>Coronary Disease</keyword>
  <keyword>Heart Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Arteriosclerosis</keyword>
  <keyword>Arterial Occlusive Diseases</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Platelet Aggregation Inhibitors</keyword>
  <keyword>Hematologic Agents</keyword>
  <keyword>Therapeutic Uses</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Purinergic P2Y Receptor Antagonists</keyword>
  <keyword>Purinergic P2 Receptor Antagonists</keyword>
  <keyword>Purinergic Antagonists</keyword>
  <keyword>Purinergic Agents</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Purinergic P2Y Receptor Antagonists</mesh_term>
    <mesh_term>Purinergic Antagonists</mesh_term>
    <mesh_term>Purinergic P2 Receptor Antagonists</mesh_term>
    <mesh_term>Physiological Effects of Drugs</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
